Skip to main content
Erschienen in: International Journal of Hematology 5/2008

01.12.2008 | Original Article

Efficacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation

verfasst von: Takehiko Mori, Kaori Hasegawa, Ai Okabe, Natsuki Tsujimura, Yusuke Kawata, Tomoko Yashima, Naoko Kobayashi, Sakiko Kondo, Yoshinobu Aisa, Jun Kato, Kazuyuki Tsunoda, Tetsuo Nagai, Taneaki Nakagawa, Naoyuki Shigematsu, Atsushi Kubo, Yasuo Ikeda, Shinichiro Okamoto

Erschienen in: International Journal of Hematology | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

High-dose cytarabine is one of the major components of the conditioning regimen for hematopoietic stem cell transplantation (HSCT), and frequently causes severe oral mucositis. We have recently demonstrated that cytarabine is excreted into the saliva in patients receiving high-dose cytarabine, and proposed that it might locally and directly contribute to the development of oral mucositis. Therefore, this study was performed to assess whether removing the excreted cytarabine in the saliva by intensive mouth rinse during high-dose cytarabine infusion could reduce the incidence of oral mucositis. Fifteen patients with hematologic malignancies undergoing allogeneic HSCT who received total body irradiation (12 Gy) and high-dose cytarabine at a dose of 3 g/m2 every 12 h for 4 days as a conditioning were evaluated. Patients were instructed to rinse their mouths using ice-cold water every 10 min, starting simultaneously with the 2-h cytarabine infusion and continuing up to 1 h after completion of each infusion. Oral mucositis was graded on a daily basis according to the National Cancer Institute, Common Toxicity Criteria. Thirty-five patients who previously underwent the same conditioning without mouth rinse served as controls. The incidence of Grades 2–3 and Grade 3 oral mucositis was significantly reduced in patients who performed mouth rinse as compared with the controls (40 vs. 80%, P = 0.009; 0 vs. 25. 7%, P = 0.02). In conclusion, mouth rinse during and shortly after high-dose cytarabine infusion could be an effective and inexpensive measure in reducing the incidence of moderate to severe oral mucositis caused by high-dose cytarabine. This finding strongly suggests the role of cytarabine excretion in the saliva in the development of cytarabine-associated oral mucositis.
Literatur
1.
Zurück zum Zitat Filicko J, Lazarus HM, Flomberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant. 2003;31:1–10. doi:10.1038/sj.bmt.1703776.CrossRefPubMed Filicko J, Lazarus HM, Flomberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant. 2003;31:1–10. doi:10.​1038/​sj.​bmt.​1703776.CrossRefPubMed
2.
Zurück zum Zitat Coccia PF, Strandjord SE, Warkentin PI, Cheung NK, Gordon EM, Novak LJ, et al. High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood. 1988;71:888–93.PubMed Coccia PF, Strandjord SE, Warkentin PI, Cheung NK, Gordon EM, Novak LJ, et al. High-dose cytosine arabinoside and fractionated total-body irradiation: an improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission. Blood. 1988;71:888–93.PubMed
3.
Zurück zum Zitat Riddell S, Appelbaum FR, Buckner CD, Stewart P, Clift R, Sanders J, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol. 1988;6:576–82.CrossRefPubMed Riddell S, Appelbaum FR, Buckner CD, Stewart P, Clift R, Sanders J, et al. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. J Clin Oncol. 1988;6:576–82.CrossRefPubMed
4.
Zurück zum Zitat Kamani N, Bayever E, August CS, Bunin N, Goldwein JW, D’Angio GJ. Fractionated toral-body irradiation preceding high-dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemia. Med Pediatr Oncol. 1995;25:179–84. doi:10.1002/mpo.2950250304.CrossRefPubMed Kamani N, Bayever E, August CS, Bunin N, Goldwein JW, D’Angio GJ. Fractionated toral-body irradiation preceding high-dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemia. Med Pediatr Oncol. 1995;25:179–84. doi:10.​1002/​mpo.​2950250304.CrossRefPubMed
5.
Zurück zum Zitat Takahashi S, Okamoto SI, Shirafuji N, Ikebuchi K, Tani K, Shimane M, et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. Bone Marrow Transplant. 1994;13:239–45.PubMed Takahashi S, Okamoto SI, Shirafuji N, Ikebuchi K, Tani K, Shimane M, et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. Bone Marrow Transplant. 1994;13:239–45.PubMed
6.
Zurück zum Zitat Okamoto S, Takahashi S, Wakui M, Ishida A, Tanosaki R, Ikeda Y, et al. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. Br J Haematol. 1999;104:569–73. doi:10.1046/j.1365-2141.1999.01205.x.CrossRefPubMed Okamoto S, Takahashi S, Wakui M, Ishida A, Tanosaki R, Ikeda Y, et al. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. Br J Haematol. 1999;104:569–73. doi:10.​1046/​j.​1365-2141.​1999.​01205.​x.CrossRefPubMed
8.
Zurück zum Zitat Mori T, Aisa Y, Yokoyama A, Nakazato T, Yamazaki R, Shimizu T, et al. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. Bone Marrow Transplant. 2007;39:217–21. doi:10.1038/sj.bmt.1705578.CrossRefPubMed Mori T, Aisa Y, Yokoyama A, Nakazato T, Yamazaki R, Shimizu T, et al. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. Bone Marrow Transplant. 2007;39:217–21. doi:10.​1038/​sj.​bmt.​1705578.CrossRefPubMed
10.
Zurück zum Zitat Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 1991;9:449–52.CrossRefPubMed Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 1991;9:449–52.CrossRefPubMed
11.
Zurück zum Zitat Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of fluorouracil-related stomatitis. Cancer. 1993;72:2234–8. doi:10.1002/1097-0142(19931001)72:7<2234::AID-CNCR2820720728>3.0.CO;2-N.CrossRefPubMed Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of fluorouracil-related stomatitis. Cancer. 1993;72:2234–8. doi:10.1002/1097-0142(19931001)72:7<2234::AID-CNCR2820720728>3.0.CO;2-N.CrossRefPubMed
13.
Zurück zum Zitat Dumonet C, Sonnet A, Bastion Y, Salles G, Espinouse D, Coiffier B. Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant. 1994;3:492–4. Dumonet C, Sonnet A, Bastion Y, Salles G, Espinouse D, Coiffier B. Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant. 1994;3:492–4.
14.
Zurück zum Zitat Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2005;13:266–9. doi:10.1007/s00520-004-0726-y.CrossRefPubMed Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2005;13:266–9. doi:10.​1007/​s00520-004-0726-y.CrossRefPubMed
15.
Zurück zum Zitat Mori T, Yamazaki R, Aisa Y, Nakazato T, Kudo M, Yashima T, et al. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2006;14:392–5. doi:10.1007/s00520-005-0016-3.CrossRefPubMed Mori T, Yamazaki R, Aisa Y, Nakazato T, Kudo M, Yashima T, et al. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2006;14:392–5. doi:10.​1007/​s00520-005-0016-3.CrossRefPubMed
16.
Zurück zum Zitat Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995;75:11–7. doi:10.1002/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N.CrossRefPubMed Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995;75:11–7. doi:10.1002/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N.CrossRefPubMed
17.
Zurück zum Zitat Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17:2412–8.CrossRefPubMed Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17:2412–8.CrossRefPubMed
18.
Zurück zum Zitat Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thürlimann B, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the international breast cancer study group trial VII. J Clin Oncol. 2000;18:1412–22.CrossRefPubMed Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thürlimann B, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the international breast cancer study group trial VII. J Clin Oncol. 2000;18:1412–22.CrossRefPubMed
19.
Zurück zum Zitat Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(Suppl 2):18–24.PubMed Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(Suppl 2):18–24.PubMed
20.
Zurück zum Zitat Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J Clin Oncol. 1984;2:545–9.CrossRefPubMed Hines JD, Oken MM, Mazza JJ, Keller AM, Streeter RR, Glick JH. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J Clin Oncol. 1984;2:545–9.CrossRefPubMed
21.
22.
Zurück zum Zitat Vogler WR, Preisler HD, Winton EF, Gottlieb AJ, Goldberg J, Brennan J, et al. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a leukemia intergroup study. Cancer Treat Rep. 1986;70:455–9.PubMed Vogler WR, Preisler HD, Winton EF, Gottlieb AJ, Goldberg J, Brennan J, et al. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a leukemia intergroup study. Cancer Treat Rep. 1986;70:455–9.PubMed
23.
Zurück zum Zitat Barrios NJ, Tebbi CK, Freeman AI, Brecher ML. Toxicity of high dose Ara-C in children and adolescents. Cancer. 1987;60:165–9. doi:10.1002/1097-0142(19870715)60:2<165::AID-CNCR2820600207>3.0.CO;2-G.CrossRefPubMed Barrios NJ, Tebbi CK, Freeman AI, Brecher ML. Toxicity of high dose Ara-C in children and adolescents. Cancer. 1987;60:165–9. doi:10.1002/1097-0142(19870715)60:2<165::AID-CNCR2820600207>3.0.CO;2-G.CrossRefPubMed
Metadaten
Titel
Efficacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation
verfasst von
Takehiko Mori
Kaori Hasegawa
Ai Okabe
Natsuki Tsujimura
Yusuke Kawata
Tomoko Yashima
Naoko Kobayashi
Sakiko Kondo
Yoshinobu Aisa
Jun Kato
Kazuyuki Tsunoda
Tetsuo Nagai
Taneaki Nakagawa
Naoyuki Shigematsu
Atsushi Kubo
Yasuo Ikeda
Shinichiro Okamoto
Publikationsdatum
01.12.2008
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2008
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-008-0181-5

Weitere Artikel der Ausgabe 5/2008

International Journal of Hematology 5/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.